Suffering and quality of life impairment in patients with eczematous diseases: results from an observational study assessing the relevance of the involvement of two sensitive body sites, namely the face and hands

Background: quality of life (QoL) impairment by eczematous diseases, with reference to body site involvement, has not been deeply addressed;Objectives: to assess: i) the impact on QoL of eczematous diseases affecting the face or hands; ii) any differences in QoL impairment in the case of face versus hands involvement; iii) sensitivity of Pictorial Representation of Illness and Self-Measure (PRISM) and Dermatology Life Quality Index (DLQI) in measuring disease-related burden; Methods: adults with eczematous diseases of the face or hands were involved. Patients were patch tested and underwent DLQI and PRISM;Results: 143 patients were included, 43.36% with face and 56.64% with hands involvement. PRISM and DLQI scores showed a moderate-to-strong inverse correlation, but PRISM revealed a higher sensitivity in capturing patients' suffering than DLQI, especially in the case of face involvement. Itching was the sole parameter significantly associated with both PRISM and DLQI scores. Conclusions: PRISM appeared to be more accurate in detecting the burden of eczematous diseases involving the face, probably due to the interception of the emotional impact, while DLQI, focusing on patient functioning, was more affected by hands involvement. Site involvement could be a criterion for selecting the best QoL assessment tool.

Automated summary

This study aimed to assess the impact of eczematous diseases on quality of life (QoL) and compare the differences between face and hand involvement. The results showed that PRISM was more accurate in reflecting the burden of eczematous diseases on the face compared to DLQI. This suggests that site involvement should be considered when selecting a QoL assessment tool.